First oral GLP-1 pill shows major promise for sleep apnea treatment

A daily pill for sleep apnea? It might be closer than you think.

The oral GLP-1 drug orforglipron (Foundayo, Eli Lilly) significantly reduced sleep apnea severity in adults with moderate to severe obstructive sleep apnea (OSA) and obesity or overweight, according to results from the two-trial ATTAIN-OSA program presented at the American Heart Association Scientific Sessions and simultaneously published in JAMA. This marks the first oral therapy to demonstrate meaningful benefits for OSA — a condition currently managed almost exclusively through CPAP masks or oral devices that many patients struggle to use consistently.

Beyond breathing, orforglipron delivered across-the-board cardiometabolic improvements, outperforming placebo on weight, inflammation, and blood pressure — benefits that even CPAP typically can't match.

By the Numbers:

• 36%–44% reduction in sleep apnea severity (non-PAP users) vs. placebo
• 26%–28% reduction in sleep apnea severity (PAP users) vs. placebo
• 72% reduction in sleep apnea-specific hypoxic burden vs. placebo
• 10%–11% body weight reduction vs. 1%–2% with placebo
• 7–8 mmHg drop in systolic BP vs. 1–3 mmHg with placebo
• 38%–42% reduction in hsCRP vs. 4%–18% with placebo

Why it matters: Sleep apnea is linked to hypertension, diabetes, heart attack, and stroke — yet it remains widely underdiagnosed and undertreated. An effective, once-daily oral option could dramatically expand access to treatment, especially for patients who can't tolerate or access injectable therapies like tirzepatide (Zepbound).